Published in Pharma Law Weekly, February 15th, 2005
The FDA recently accepted to review Spectrum Pharmaceuticals, Inc.'s Abbreviated New Drug Application (ANDA) with a Paragraph IV certification for sumatriptan succinate injection.
This compound is a generic version of GlaxoSmithKline's Imitrex injections used to treated migraines. As the first to file an ANDA, Spectrum believes it is entitled to receive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.